Physician profile
Daneeque Woolfolk
NPI 1285927269
$9,803.67
in general payments reported to CMS, 2019-2025
32 companies · $1,529 in 2025
The $1,529 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,761 · 2020: $497 · 2021: $156 · 2022: $2,339 · 2023: $1,074 · 2024: $1,448 · 2025: $1,529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,849 · Education: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,849.36 |
| Education | $202.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $1,646.66 | 2019-2022 | |
| Abbvie INC. | $1,453.32 | 2019-2025 | Skyrizi, Rinvoq |
| Leo Pharma INC. | $1,074.86 | 2019-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $813.08 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $528.90 | 2019-2025 | Dupixent |
| Janssen Biotech, INC. | $426.85 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Galderma Laboratories, L.P. | $406.22 | 2019-2025 | Nemluvio |
| Lilly USA, LLC | $360.10 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $345.11 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $315.52 | 2019-2025 | Absorica Ld, Winlevi |
| Amgen INC. | $307.20 | 2019-2025 | Otezla, Otezla |
| Incyte Corporation | $259.36 | 2022-2025 | Opzelura |
| Pfizer INC. | $238.54 | 2019-2025 | |
| Dermavant Sciences, INC. | $186.00 | 2022-2024 | Vtama |
| Almirall LLC | $172.92 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $164.62 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.81 | 2022-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $129.42 | 2019-2025 | Cabtreo |
| E.R. Squibb & Sons, L.L.C. | $125.13 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $108.06 | 2019-2020 | |
| Ucb, INC. | $102.75 | 2024-2025 | Bimzelx |
| Dermira, INC. | $78.08 | 2019-2020 | |
| Taro Pharmaceuticals USA, INC. | $73.63 | 2019 | |
| Vyne Pharmaceuticals INC. | $69.08 | 2020 | |
| Prugen, INC. Pharmaceuticals | $51.51 | 2019 | |
| Organon LLC | $49.65 | 2025 | Vtama |
| Journey Medical Corporation | $40.01 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $38.90 | 2019 | |
| Sanofi-Aventis U.S. LLC | $38.15 | 2019 | |
| Mayne Pharma Commercial LLC | $30.11 | 2019 | |
| Encore Dermatology INC. | $19.11 | 2019 | |
| Botanix Sb INC | $17.01 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daneeque Woolfolk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.